BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rojanarat W, Nakpheng T, Thawithong E, Yanyium N, Srichana T. Levofloxacin-proliposomes: opportunities for use in lung tuberculosis. Pharmaceutics 2012;4:385-412. [PMID: 24300299 DOI: 10.3390/pharmaceutics4030385] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Mehta P, Bothiraja C, Kadam S, Pawar A. Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future. Artificial Cells, Nanomedicine, and Biotechnology 2018;46:S791-806. [DOI: 10.1080/21691401.2018.1513938] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
2 Pattni BS, Chupin VV, Torchilin VP. New Developments in Liposomal Drug Delivery. Chem Rev 2015;115:10938-66. [PMID: 26010257 DOI: 10.1021/acs.chemrev.5b00046] [Cited by in Crossref: 772] [Cited by in F6Publishing: 664] [Article Influence: 110.3] [Reference Citation Analysis]
3 Mehta PP, Ghoshal D, Pawar AP, Kadam SS, Dhapte-pawar VS. Recent advances in inhalable liposomes for treatment of pulmonary diseases: Concept to clinical stance. Journal of Drug Delivery Science and Technology 2020;56:101509. [DOI: 10.1016/j.jddst.2020.101509] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
4 Ye T, Yu J, Luo Q, Wang S, Chan H. Inhalable clarithromycin liposomal dry powders using ultrasonic spray freeze drying. Powder Technology 2017;305:63-70. [DOI: 10.1016/j.powtec.2016.09.053] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
5 El-megharbel SM, Hegab MS, Manaaa EA, Al-humaidi JY, Refat MS. Synthesis and physicochemical characterizations of coordination between palladium( ii ) metal ions with floroquinolone drugs as medicinal model against cancer cells: novel metallopharmaceuticals. New J Chem 2018;42:9709-19. [DOI: 10.1039/c8nj01045e] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Patil TS, Deshpande AS. Nanostructured lipid carriers-based drug delivery for treating various lung diseases: A State‐of‐the‐Art Review. International Journal of Pharmaceutics 2018;547:209-25. [DOI: 10.1016/j.ijpharm.2018.05.070] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
7 Parumasivam T, Chang RY, Abdelghany S, Ye TT, Britton WJ, Chan HK. Dry powder inhalable formulations for anti-tubercular therapy. Adv Drug Deliv Rev 2016;102:83-101. [PMID: 27212477 DOI: 10.1016/j.addr.2016.05.011] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
8 O'Connor G, Gleeson LE, Fagan-Murphy A, Cryan SA, O'Sullivan MP, Keane J. Sharpening nature's tools for efficient tuberculosis control: A review of the potential role and development of host-directed therapies and strategies for targeted respiratory delivery. Adv Drug Deliv Rev 2016;102:33-54. [PMID: 27151307 DOI: 10.1016/j.addr.2016.04.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
9 Gaspar MC, Sousa JJ, Pais AA, Cardoso O, Murtinho D, Serra ME, Tewes F, Olivier JC. Optimization of levofloxacin-loaded crosslinked chitosan microspheres for inhaled aerosol therapy. Eur J Pharm Biopharm 2015;96:65-75. [PMID: 26192459 DOI: 10.1016/j.ejpb.2015.07.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
10 Maurya P, Saklani R, Singh S, Nisha R, Pal RR, Mishra N, Singh P, Kumar A, Chourasia MK, Saraf SA. Appraisal of fluoroquinolone-loaded carubinose-linked hybrid nanoparticles for glycotargeting to alveolar macrophages. Drug Deliv Transl Res 2021. [PMID: 34476764 DOI: 10.1007/s13346-021-01055-9] [Reference Citation Analysis]
11 Patil-Gadhe AA, Kyadarkunte AY, Pereira M, Jejurikar G, Patole MS, Risbud A, Pokharkar VB. Rifapentine-proliposomes for inhalation: in vitro and in vivo toxicity. Toxicol Int 2014;21:275-82. [PMID: 25948966 DOI: 10.4103/0971-6580.155361] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
12 Nainwal N, Sharma Y, Jakhmola V. Dry powder inhalers of antitubercular drugs. Tuberculosis (Edinb) 2022;135:102228. [PMID: 35779497 DOI: 10.1016/j.tube.2022.102228] [Reference Citation Analysis]
13 Mehanna MM, Mohyeldin SM, Elgindy NA. Respirable nanocarriers as a promising strategy for antitubercular drug delivery. J Control Release 2014;187:183-97. [PMID: 24878180 DOI: 10.1016/j.jconrel.2014.05.038] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 8.0] [Reference Citation Analysis]
14 Dua K, Hansbro NG, Foster PS, Hansbro PM. MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases. Drug Deliv and Transl Res 2017;7:168-78. [DOI: 10.1007/s13346-016-0343-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
15 Mohanty D, Zafar A, Jafar M, Upadhyay AK, Haque MA, Gupta JK, Bakshi V, Ghoneim MM, Alshehri S, Jahangir MA, Ansari MJ. Development, In-Vitro Characterization and Preclinical Evaluation of Esomeprazole-Encapsulated Proniosomal Formulation for the Enhancement of Anti-Ulcer Activity. Molecules 2022;27:2748. [PMID: 35566099 DOI: 10.3390/molecules27092748] [Reference Citation Analysis]
16 Tan ZM, Lai GP, Pandey M, Srichana T, Pichika MR, Gorain B, Bhattamishra SK, Choudhury H. Novel Approaches for the Treatment of Pulmonary Tuberculosis. Pharmaceutics 2020;12:E1196. [PMID: 33321797 DOI: 10.3390/pharmaceutics12121196] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
17 Dhiman N, Sarvaiya J, Mohindroo P. A drift on liposomes to proliposomes: recent advances and promising approaches. J Liposome Res 2022;:1-15. [PMID: 35037565 DOI: 10.1080/08982104.2021.2019762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Pham DD, Fattal E, Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment. Int J Pharm 2015;478:517-29. [PMID: 25499020 DOI: 10.1016/j.ijpharm.2014.12.009] [Cited by in Crossref: 102] [Cited by in F6Publishing: 78] [Article Influence: 12.8] [Reference Citation Analysis]
19 Dua K, Rapalli VK, Shukla SD, Singhvi G, Shastri MD, Chellappan DK, Satija S, Mehta M, Gulati M, Pinto TDJA, Gupta G, Hansbro PM. Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: Emerging need for novel drug delivery approaches. Biomedicine & Pharmacotherapy 2018;107:1218-29. [DOI: 10.1016/j.biopha.2018.08.101] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 10.5] [Reference Citation Analysis]
20 Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, Yew WW, Lange C, Chang KC. Novel drugs against tuberculosis: a clinician's perspective. Eur Respir J 2015;45:1119-31. [PMID: 25431273 DOI: 10.1183/09031936.00162314] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
21 Gallo L, Verónica Ramírez-rigo M, Bucalá V. Development of porous spray-dried inhalable particles using an organic solvent-free technique. Powder Technology 2019;342:642-52. [DOI: 10.1016/j.powtec.2018.10.041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
22 Patil-gadhe A, Pokharkar V. Single step spray drying method to develop proliposomes for inhalation: A systematic study based on quality by design approach. Pulmonary Pharmacology & Therapeutics 2014;27:197-207. [DOI: 10.1016/j.pupt.2013.07.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
23 Patil TS, Deshpande AS, Deshpande S, Shende P. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need. Journal of Drug Targeting 2019;27:12-27. [DOI: 10.1080/1061186x.2018.1455842] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
24 Banaschewski B, Hofmann T. Inhaled Antibiotics for Mycobacterial Lung Disease. Pharmaceutics 2019;11:E352. [PMID: 31331119 DOI: 10.3390/pharmaceutics11070352] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
25 Kaewiad K, Nakpheng T, Srichana T. Dental floss impregnated with povidone-iodine coated with Eudragit L-100 as an antimicrobial delivery system against periodontal-associated pathogens. Journal of Medical Microbiology 2020;69:298-308. [DOI: 10.1099/jmm.0.001126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Wei Y, Zhang J, Zheng Y, Gong Y, Fu M, Liu C, Xu L, Sun CC, Gao Y, Qian S. Cubosomes with surface cross-linked chitosan exhibit sustained release and bioavailability enhancement for vinpocetine. RSC Adv 2019;9:6287-98. [DOI: 10.1039/c8ra10302j] [Cited by in Crossref: 9] [Article Influence: 3.0] [Reference Citation Analysis]
27 Shah SR, Prajapati HR, Sheth DB, Gondaliya EM, Vyas AJ, Soniwala MM, Chavda JR. Pharmacokinetics and in vivo distribution of optimized PLGA nanoparticles for pulmonary delivery of levofloxacin. J Pharm Pharmacol 2020;72:1026-37. [PMID: 32337714 DOI: 10.1111/jphp.13275] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
28 Alves A, Correia-da-Silva M, Nunes C, Campos J, Sousa E, Silva PMA, Bousbaa H, Rodrigues F, Ferreira D, Costa PC, Pinto M. Discovery of a New Xanthone against Glioma: Synthesis and Development of (Pro)liposome Formulations. Molecules 2019;24:E409. [PMID: 30678085 DOI: 10.3390/molecules24030409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
29 Ferraz-Carvalho RS, Pereira MA, Linhares LA, Lira-Nogueira MC, Cavalcanti IM, Santos-Magalhães NS, Montenegro LM. Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates. Mem Inst Oswaldo Cruz 2016;111:330-4. [PMID: 27143488 DOI: 10.1590/0074-02760150454] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
30 Khan I, Yousaf S, Najlah M, Ahmed W, Elhissi A. Proliposome powder or tablets for generating inhalable liposomes using a medical nebulizer. J Pharm Investig 2021;51:61-73. [DOI: 10.1007/s40005-020-00495-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
31 Laohapojanart N, Ratanajamit C, Kawkitinarong K, Srichana T. Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial. Pulm Pharmacol Ther 2021;70:102056. [PMID: 34273498 DOI: 10.1016/j.pupt.2021.102056] [Reference Citation Analysis]
32 Ahmad MI, Nakpheng T, Srichana T. The safety of ethambutol dihydrochloride dry powder formulations containing chitosan for the possibility of treating lung tuberculosis. Inhalation Toxicology 2014;26:908-17. [DOI: 10.3109/08958378.2014.975875] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]